date:Feb 21, 2013
elivered growth across all clusters in 2012, excluding caprolactam, said Feike Sijbesma, CEO/chairman of the DSM Managing Board. Nutrition now represents more than 70% of total EBITDA and has become a high value, global business with attractive growth prospects across the full value chain.
The significant strategic progress we made during 2012 through our value creating acquisitions and the profit improvement initiatives we have taken leave us well positioned to achieve our long term objectives